Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 1:15 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1945–1968 of 6,600 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Multi Center Clear all

Conditions: Solid Tumors
Interventions: ALN-VSP02; Drug
Lead sponsor: Alnylam Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 7
States / cities: Scottsdale, Arizona • Boston, Massachusetts • Detroit, Michigan + 2 more

Conditions: Acne Vulgaris
Interventions: Clindamycin Phosphate, Clindamycin Phosphate RLD, Placebos; Drug
Lead sponsor: Sun Pharmaceutical Industries, Inc.; Industry
Eligibility: 12 Years to 40 Years
Enrollment: 550 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Charlotte, North Carolina

Conditions: Overweight , Obesity, Adults
Interventions: ALV-100, Placebo; Drug
Lead sponsor: Alveus Therapeutics, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 20
States / cities: Birmingham, Alabama • Sun City, Arizona • Tempe, Arizona + 16 more

Conditions: Eosinophilic Esophagitis
Interventions: RPC4046, Placebo; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 27
States / cities: Scottsdale, Arizona • Tucson, Arizona • Oceanside, California + 24 more

Conditions: Neoplasms, Brain
Interventions: Dabrafenib; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 12 Months to 17 Years
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2020
U.S. locations: 8
States / cities: Phoenix, Arizona • Orange, California • Baltimore, Maryland + 5 more

Conditions: Chronic Myelogenous Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Interventions: Asciminib single agent, Imatinib, Nilotinib, Bosutinib, Dasatinib, Asciminib single agent pediatric formulation; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 7 Years to 100 Years
Enrollment: 347 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2030
U.S. locations: 6
States / cities: Ann Arbor, Michigan • New York, New York • Portland, Oregon + 3 more

Conditions: Urinary Bladder Diseases, Urinary Bladder Overactive, Urologic Diseases
Interventions: mirabegron 25 mg, mirabegron 50 mg, solifenacin 5 mg, solifenacin 10 mg, mirabegron 25 mg matching placebo, mirabegron 50 mg matching placebo, solifenacin 5 mg matching placebo, solifenacin 10 mg matching placebo; Drug
Lead sponsor: Astellas Pharma Europe Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 2,174 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 36
States / cities: Tucson, Arizona • Buena Park, California • Los Angeles, California + 31 more

Conditions: Anemia
Interventions: Ferric Carboxymaltose, Standard Medical Care (SMC); Drug
Lead sponsor: American Regent, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 735 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Norristown, Pennsylvania

Conditions: ERCP
Interventions: Not listed
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years to 100 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Chronic Pain
Interventions: Burst-capable SCS system, DRG Stimulator; Device
Lead sponsor: Abbott Medical Devices; Industry
Eligibility: 18 Years and older
Enrollment: 118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 21
States / cities: Camarillo, California • Carlsbad, California • La Jolla, California + 18 more

Conditions: Liver Diseases
Interventions: Etavopivat; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 5
States / cities: Orange, California • Orlando, Florida • San Antonio, Texas

Conditions: Abdominal Obesity
Interventions: Experimental: eonTM FR 1064 nm device; Device
Lead sponsor: Dominion Aesthetic Technologies, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Altamonte Springs, Florida

Conditions: Arthritis of the Knee
Interventions: iovera°, iovera° Sham; Device
Lead sponsor: Pacira Pharmaceuticals, Inc; Industry
Eligibility: 22 Years to 79 Years
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 8
States / cities: San Diego, California • Englewood, Colorado • Fort Lauderdale, Florida + 5 more

Conditions: Venus Leg Ulcers
Interventions: Promogran, Coban 2 layer; Device
Lead sponsor: Systagenix Wound Management; Industry
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Eire, Pennsylvania

Conditions: Dry Eye, Dry Eye Syndromes
Interventions: Vehicle Ophthalmic Solution, PL9643 Ophthalmic Solution; Drug
Lead sponsor: Palatin Technologies, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 575 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 18
States / cities: Glendale, California • Newport Beach, California • Torrance, California + 15 more

Conditions: Multiple Sclerosis
Interventions: Not listed
Lead sponsor: University of South Florida; Other
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Tattoo Removal
Interventions: enLighten Laser; Device
Lead sponsor: Cutera Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 2
States / cities: Brisbane, California • Chestnut Hill, Massachusetts

Conditions: B-cell Acute Lymphoblastic Leukemia
Interventions: forodesine hydrochloride (BCX-1777); Drug
Lead sponsor: BioCryst Pharmaceuticals; Industry
Eligibility: Not listed
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 7
States / cities: Denver, Colorado • Chicago, Illinois • Kansas City, Kansas + 3 more

Conditions: Psoriasis
Interventions: clobetasol propionate spray 0.05%, calcitriol ointment; Drug
Lead sponsor: Galderma R&D; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 305 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 12
States / cities: San Diego, California • Newnan, Georgia • Snellville, Georgia + 9 more

Conditions: Proteinuria
Interventions: Belatacept; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Depression
Interventions: AZD6765; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 21 Years to 65 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007
U.S. locations: 5
States / cities: Glendale, California • Hartford, Connecticut • New Haven, Connecticut + 2 more

Conditions: Diabetic Nephropathy
Interventions: Sevelamer Carbonate, calcium carbonate; Drug
Lead sponsor: Gary Striker; Other
Eligibility: 18 Years and older
Enrollment: 117 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 2
States / cities: New York, New York

Conditions: Alzheimer's Disease
Interventions: ITI-007, Placebo; Drug
Lead sponsor: Intra-Cellular Therapies, Inc.; Industry
Eligibility: 65 Years and older
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Glendale, California

Conditions: Parkinson's Disease, Multiple System Atrophy, Parkinson Variant, Multiple System Atrophy
Interventions: This is an observational study.; Other
Lead sponsor: AskBio Inc; Industry
Eligibility: 35 Years to 75 Years
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 7
States / cities: Irvine, California • Boca Raton, Florida • Boston, Massachusetts + 4 more

Search by objective public record fields.

Multi-center, Open Label, Extension Study of ALN-VSP02 in Cancer Patients Who Have Responded to ALN-VSP02 Treatment

Bio-equivalence Study With Clinical Endpoints in the Treatment of Acne Vulgaris

Study to Assess the Effect and Safety of ALV-100 on Maintenance of Weight Loss

Dose Ranging Study of RPC4046 in Eosinophilic Esophagitis

A Study to Determine Safety, Tolerability and Pharmacokinetics of Oral Dabrafenib In Children and Adolescent Subjects

Asciminib Roll-over Study

A Trial Comparing Combination Treatment (Solifenacin Plus Mirabegron) With One Treatment Alone (Solifenacin)

Safety and Tolerability of a Single Dose of FCM vs. Standard of Care in Treating Iron Deficiency Anemia

Prospective Evaluation of Performance of Disposable Elevator Cap Duodenoscope During ERCP in Clinical Practice

PROLONG Prospective, Multi-center, Open-label, Post-market Study

A Research Study on Etavopivat in Participants With and Without Liver Disease

Eon™ FR 1064 Full Abdomen Clinical Study Protocol

A Randomized, Study to Evaluate the Iovera° Device in Treating Pain Associated With Total Knee Arthroplasty

WOUNDCHEK™ Protease Status Point of Care (POC) Diagnostic Test

A Phase 3, Multi-Center Study Evaluating PL9643 in Patients with Dry Eye

Adherence to Treatment With Tecfidera™ in Multiple Sclerosis Patients

Multi-Wavelength Laser Tattoo Removal Pivotal Study

Forodesine Hydrochloride (BCX-1777) for B-Cell Acute Lymphoblastic Leukemia

Safety & Effectiveness of Clobex Spray, Followed by Calcitriol Ointment in Management of Plaque Psoriasis

Belatacept Conversion in Proteinuric Kidney Transplant Recipients

AZD6765 for Treatment Resistant Depression

The Effects of Sevelamer Carbonate on Diabetic Nephropathy

Study of ITI-007 in Healthy Geriatric Volunteers and in Geriatric Patients With Dementia

Pre-Gene Therapy Study in Parkinson's Disease and Multiple System Atrophy